Overview and recent advances in the treatment of neuroblastoma
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Rassi, A., Rassi, A., & Marin-Neto, J. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60061-x · Cited by 2,119
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 1×
“18 (dinutuximab) with cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) to standard isotretinoin maintenance therapy significantly improved shortterm survival in high-risk patients, with both higher EFS and OS rates compared to standard therapy after two years of follow-up [8…”
BackgroundIdentification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407 · cited 11×
“One of the most exciting recent success stories in neuroblastoma treatment is the recent discovery of a key role for the anaplastic lymphoma kinase (ALK) in the pathogenesis of familial neuroblastoma [19–22].”
BackgroundInfluentialTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Brodeur, G. M., Seeger, R. C., Barrett, A., Berthold, F., Castleberry, R. P., D'Angio, G., De Bernardi, B., Evans, A. E., Favrot, M., & Freeman, A. I. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1874 · Cited by 608
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., & Roald, B. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<349::aid-cncr20>3.0.co;2-y · Cited by 586
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 573
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J., Joshi, V. V., & Roald, B. (1999) · PubMed · Cited by 573
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3333 · Cited by 540
Neuroblastoma Screening at One Year of Age
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 411
Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70291-6 · Cited by 402
Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Germline Mutations of the Paired–Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., Schleiermacher, G., Coze, C., Philip, N., Frébourg, T., Munnich, A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383253 · Cited by 358
Screening of Infants and Mortality Due to Neuroblastoma
Woods, W. G., Gao, R.-N., Shuster, J. J., Robison, L. L., Bernstein, M., Weitzman, S., Bunin, G., Levy, I., Brossard, J., Dougherty, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012387 · Cited by 356
Copy number variation at 1q21.1 associated with neuroblastoma
Diskin, S. J., Hou, C., Glessner, J. T., Attiyeh, E. F., Laudenslager, M., Bosse, K., Cole, K., Mossé, Y. P., Wood, A., Lynch, J. E., et al. (2009) · Nature · doi:10.1038/nature08035 · Cited by 354
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 326
Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma
Maris, J. M., Mosse, Y. P., Bradfield, J. P., Hou, C., Monni, S., Scott, R. H., Asgharzadeh, S., Attiyeh, E. F., Diskin, S. J., Laudenslager, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708698 · Cited by 319
London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3392 · Cited by 318
Saylors, R. L., Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bernstein, M. L., Harris, M. B., Hayashi, R., & Vietti for the Pediatric Oncology Group, T. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3463 · Cited by 315
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Wang, K., Diskin, S. J., Zhang, H., Attiyeh, E. F., Winter, C., Hou, C., Schnepp, R. W., Diamond, M., Bosse, K., Mayes, P. A., et al. (2011) · Nature · doi:10.1038/nature09609 · Cited by 310
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Capasso, M., Devoto, M., Hou, C., Asgharzadeh, S., Glessner, J. T., Attiyeh, E. F., Mosse, Y. P., Kim, C., Diskin, S. J., Cole, K. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.374 · Cited by 305
Kreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
Jena, B., Dotti, G., & Cooper, L. J. N. (2010) · Blood · doi:10.1182/blood-2010-01-043737 · Cited by 297
Germline PHOX2B Mutation in Hereditary Neuroblastoma
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284
Carén, H., Abel, F., Kogner, P., & Martinsson, T. (2008) · Biochemical Journal · doi:10.1042/bj20081834 · Cited by 280
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2387 · Cited by 266
Matthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.-C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3484 · Cited by 264
Cheung, N.-K. V., Cheung, I. Y., Kushner, B. H., Ostrovnaya, I., Chamberlain, E., Kramer, K., & Modak, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3807 · Cited by 263
ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
Hogarty, M. D., Norris, M. D., Davis, K., Liu, X., Evageliou, N. F., Hayes, C. S., Pawel, B., Guo, R., Zhao, H., Sekyere, E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6866 · Cited by 262
Cole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., Diskin, S. J., Attiyeh, E. F., Sennett, R., Norris, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012351108 · Cited by 249
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Strother, D. R., London, W. B., Schmidt, M. L., Brodeur, G. M., Shimada, H., Thorner, P., Collins, M. H., Tagge, E., Adkins, S., Reynolds, C. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9990 · Cited by 234
Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L., Barr, F. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2056 · Cited by 232
Hölzel, M., Huang, S., Koster, J., Øra, I., Lakeman, A., Caron, H., Nijkamp, W., Xie, J., Callens, T., Asgharzadeh, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.004 · Cited by 224
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0674 · Cited by 215
Yanik, G. A., Parisi, M. T., Shulkin, B. L., Naranjo, A., Kreissman, S. G., London, W. B., Villablanca, J. G., Maris, J. M., Park, J. R., Cohn, S. L., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112334 · Cited by 211
Nuchtern, J. G., London, W. B., Barnewolt, C. E., Naranjo, A., McGrady, P. W., Geiger, J. D., Diller, L., Schmidt, M. L., Maris, J. M., Cohn, S. L., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826cbbbd · Cited by 200
Cheung, N. K., Kushner, B. H., Cheung, I. Y., Kramer, K., Canete, A., Gerald, W., Bonilla, M. A., Finn, R., Yeh, S. J., & Larson, S. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3053 · Cited by 199
Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Laverdière, C., Liu, Q., Yasui, Y., Nathan, P. C., Gurney, J. G., Stovall, M., Diller, L. R., Cheung, N.-K., Wolden, S., Robison, L. L., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp230 · Cited by 189
Delgado, D. C., Hank, J. A., Kolesar, J., Lorentzen, D., Gan, J., Seo, S., Kim, K., Shusterman, S., Gillies, S. D., Reisfeld, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2211 · Cited by 179
Passoni, L., Longo, L., Collini, P., Coluccia, A. M. L., Bozzi, F., Podda, M., Gregorio, A., Gambini, C., Garaventa, A., Pistoia, V., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4419 · Cited by 173
The epidemiology of neuroblastoma: a review
Heck, J. E., Ritz, B., Hung, R. J., Hashibe, M., & Boffetta, P. (2009) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2008.00983.x · Cited by 170
Long‐term complications in survivors of advanced stage neuroblastoma
Laverdière, C., Cheung, N. V., Kushner, B. H., Kramer, K., Modak, S., LaQuaglia, M. P., Wolden, S., Ness, K. K., Gurney, J. G., & Sklar, C. A. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20331 · Cited by 169
Lashford, L. S., Lewis, I. J., Fielding, S. L., Flower, M. A., Meller, S., Kemshead, J. T., & Ackery, D. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1889 · Cited by 163
Bagatell, R., London, W. B., Wagner, L. M., Voss, S. D., Stewart, C. F., Maris, J. M., Kretschmar, C., & Cohn, S. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.7107 · Cited by 160
Simon, T., Häberle, B., Hero, B., von Schweinitz, D., & Berthold, F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9339 · Cited by 158
Henderson, T. O., Bhatia, R., Pinto, N. R., London, W. B., McGrady, P., Crotty, C., Sun, C., & Cohn, S. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6103 · Cited by 154
Sholler, G. L. S., Gerner, E. W., Bergendahl, G., MacArthur, R. B., VanderWerff, A., Ashikaga, T., Bond, J. P., Ferguson, W. S., Roberts, W. D., Wada, R. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127246 · Cited by 152
Yalçın, B., Kremer, L. C. M., & van Dalen, E. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006301.pub4 · Cited by 148
Bomgaars, L. R., Bernstein, M., Krailo, M., Kadota, R., Das, S., Chen, Z., Adamson, P. C., & Blaney, S. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6103 · Cited by 141
Update on diagnosis, treatment, and prognosis in opsoclonus–myoclonus–ataxia syndrome
Gorman, M. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32833fde3f · Cited by 140
Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma
Kushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7272 · Cited by 137
London, W. B., Frantz, C. N., Campbell, L., Seeger, R. C., Brumback, B., Cohn, S. L., Matthay, K. K., Castleberry, R. P., & Diller, L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5016 · Cited by 136
Bernardi, B. D., Mosseri, V., Rubie, H., Castel, V., Foot, A. B. M., Ladenstein, R. L., Laureys, G., Popovic, M. B., Lacerda, A., Pearson, A. D. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604640 · Cited by 132
DuBois, S. G., Marachelian, A., Fox, E., Kudgus, R. A., Reid, J. M., Groshen, S. G., Malvar, J., Bagatell, R., Wagner, L. M., Maris, J. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.4889 · Cited by 132
Twist, C. J., Schmidt, M. L., Naranjo, A. H., London, W. B., Tenney, S. C., Marachelian, A., Shimada, H., Collins, M. H., Esiashvili, N., Adkins, E. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00919 · Cited by 131
Garaventa, A., Parodi, S., Bernardi, B. D., Dau, D., Manzitti, C., Conte, M., Casale, F., Viscardi, E., Bianchi, M., D’Angelo, P., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.010 · Cited by 129
Cheung, N. V., Sowers, R. S., Vickers, A. J., Cheung, I. Y., Kushner, B. H., & Gorlick, R. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6011 · Cited by 129
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Lee, D. W., Barrett, D. M., Mackall, C., Orentas, R., & Grupp, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1920 · Cited by 127
Schulte, J. H., Bachmann, H. S., Brockmeyer, B., Preter, K. D., Oberthür, A., Ackermann, S., Kahlert, Y., Pajtler, K. W., Theißen, J., Westermann, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2809 · Cited by 122
Mossé, Y. P., Lipsitz, E. G., Fox, E., Teachey, D. T., Maris, J. M., Weigel, B. J., Adamson, P. C., Ingle, M. A., Ahern, C. H., & Blaney, S. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3251 · Cited by 120
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Blaney, S. M., Berg, S. L., Pratt, C. B., Weitman, S., Sullivan, J., Luchtman‐Jones, L., & Bernstein, M. L. (2001) · PubMed · Cited by 117
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
Merchant, M. S., Geller, J. I., Baird, K., Chou, A. J., Galli, S., Charles, A., Amaoko, M., Rhee, E. H., Price, A., Wexler, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1055 · Cited by 115
Mossé, Y. P., Deyell, R. J., Berthold, F., Nagakawara, A., Ambros, P. F., Monclair, T. F., Cohn, S. L., Pearson, A. D. J., London, W. B., & Matthay, K. K. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24777 · Cited by 114
Cohen, L. E., Gordon, J. H., Popovsky, E. Y., Gunawardene, S. C., Duffey-Lind, E. C., Lehmann, L., & Diller, L. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.218 · Cited by 104
Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy
Doyen, J., Falk, A. T., Floquet, V., Hérault, J., & Hannoun‐Lévi, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.007 · Cited by 102
Moreno, L., Rubie, H., Varo, A., Deley, M. L., Amoroso, L., Chevance, A., Garaventa, A., Gambart, M., Bautista, F. J., Valteau‐Couanet, D., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26192 · Cited by 100
Schleiermacher, G., Michon, J. M., Ribeiro, A., Pierron, G., Mosseri, V., Rubie, H., Munzer, C., Bénard, J., Auger, N., Combaret, V., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.472 · Cited by 99
Garaventa, A., Luksch, R., Biasotti, S., Severi, G., Pizzitola, M. R., Viscardi, E., Prete, A., Mastrangelo, S., Podda, M. G., Haupt, R., et al. (2003) · Cancer · doi:10.1002/cncr.11797 · Cited by 98
Grinshtein, N., Datti, A., Fujitani, M., Uehling, D., Prakesch, M. A., Isaac, M. B., Irwin, M. S., Wrana, J. L., Al‐awar, R., & Kaplan, D. R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2484 · Cited by 96
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma
Bleeker, G., Tytgat, G. A. M., Adam, J. A., Caron, H. N., Kremer, L. C. M., Hooft, L., & van Dalen, E. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009263.pub2 · Cited by 96
Moore, N. F., Azarova, A. M., Bhatnagar, N., Ross, K. N., Drake, L. E., Frumm, S. M., Liu, Q. S., Christie, A. L., Sanda, T., Chesler, L., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2372 · Cited by 96
Yamamoto, K., Ohta, S., Ito, E., Hayashi, Y., Asami, T., Mabuchi, O., Higashigawa, M., & Tanimura, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1209 · Cited by 84
Systematic Review of Chromium and Nickel Exposure During Pregnancy and Impact on Child Outcomes
McDermott, S. W., Salzberg, D., Anderson, A. P., Shaw, T. F., & Lead, J. R. (2015) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2015.1090939 · Cited by 81
Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Bellini, A., Bernard, V., Leroy, Q., Frio, T. R., Pierron, G., Combaret, V., Lapouble, E., Clément, N., Rubie, H., Thébaud, E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0423 · Cited by 78
Day Care, Childhood Infections, and Risk of Neuroblastoma
Menegaux, F. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh111 · Cited by 75
Pession, A., & Tonelli, R. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009054064606 · Cited by 73
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
Woodfield, S. E., Zhang, L., Scorsone, K. A., Liu, Y., & Zage, P. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2199-z · Cited by 73
Self-citationSecond malignancies in patients with neuroblastoma: The effects of risk‐based therapy
Applebaum, M. A., Henderson, T. O., Lee, S. M., Pinto, N. R., Volchenboum, S. L., & Cohn, S. L. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25249 · Cited by 71
Blaney, S. M., Needle, M. N., Gillespie, A., Sato, J. K., Reaman, G. H., Berg, S. L., Adamson, P. C., Krailo, M., Bleyer, W. A., Poplack, D. G., et al. (1998) · PubMed · Cited by 68
Park, J. R., Kreissman, S. G., London, W. B., Naranjo, A. H., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D. A., Shaw, P. J., Geiger, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.18_suppl.lba3 · Cited by 66
Proton Radiotherapy for High-Risk Pediatric Neuroblastoma: Early Outcomes and Dose Comparison
Hattangadi, J. A., Rombi, B., Yock, T. I., Broussard, G., Friedmann, A. M., Huang, M., Chen, Y.-L. E., Lu, H., Kooy, H. M., & MacDonald, S. M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.08.035 · Cited by 63
Clausen, N., Andersson, P., & Tommerup, N. (1989) · Acta Paediatrica · doi:10.1111/j.1651-2227.1989.tb11135.x · Cited by 61
Quach, A., Ji, L., Mishra, V., Sznewajs, A., Veatch, J., Huberty, J., Franc, B., Sposto, R., Groshen, S., Wei, D., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22767 · Cited by 60 · cited 1×
“MIBG therapy in particular has been linked to new-onset thyroid dysfunction, secondary leukemias, and myelodysplastic syndrome in early studies [173,174].”
BackgroundFactors Influencing Survival in Children With Recurrent Neuroblastoma
Lau, L. M. S., Tai, D., Weitzman, S. S., Grant, R. M., Baruchel, S., & Malkin, D. M. (2004) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200404000-00003 · Cited by 59
Polishchuk, A. L., DuBois, S. G., Haas-Kogan, D. A., Hawkins, R. A., & Matthay, K. K. (2011) · Cancer · doi:10.1002/cncr.25987 · Cited by 55
Balamuth, N., Wood, A., Wang, Q., Jagannathan, J., Mayes, P. A., Zhang, Z., Chen, Z., Rappaport, E. R., Courtright, J., Pawel, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3844 · Cited by 54
Mazloom, A., Louis, C. U., Nuchtern, J. G., Kim, E. S., Russell, H. V., Allen‐Rhoades, W. A., Krance, R. A., & Paulino, A. C. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.07.019 · Cited by 54
Seif, A. E., Naranjo, A. H., Baker, D. L., Bunin, N., Kletzel, M., Kretschmar, C., Maris, J. M., McGrady, P., von Allmen, D., Cohn, S. L., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.276 · Cited by 50
Long‐term follow‐up of children with high‐risk neuroblastoma: The ENSG5 trial experience
Moreno, L., Vaidya, S. J., Pinkerton, R., Lewis, I. J., Imeson, J., Machin, D., Pearson, A. D. J., & on behalf of the European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG) (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24452 · Cited by 48
Initial testing of topotecan by the pediatric preclinical testing program
Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R. G., Reynolds, C. P., Kang, M. H., Maris, J. M., Keir, S. T., Watkins, A., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22352 · Cited by 47
Oppenheimer, O., Cheung, N. V., & Gerald, W. L. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0587 · Cited by 47
Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma
Krishnadas, D. K., Shapiro, T., & Lucas, K. G. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0376 · Cited by 46
Peirce, S. K., Findley, H. W., Prince, C. Z., Dasgupta, A., Cooper, T. M., & Durden, D. L. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1486-7 · Cited by 42
Pasqualini, C., Dufour, C., Goma, G., Raquin, M., Lapierre, V., & Valteau‐Couanet, D. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.264 · Cited by 41
Hawkins, D. S., Bradfield, S. M., Whitlock, J. A., Krailo, M., Franklin, J. R., Blaney, S. M., Adamson, P. C., & Reaman, G. H. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20739 · Cited by 41
New aspects of neuroblastoma treatment: ASPHO 2011 symposium review
Zage, P. E., Louis, C. U., & Cohn, S. L. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24116 · Cited by 34
Self-citationSubsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma
Federico, S. M., Allewelt, H. B., Spunt, S. L., Hudson, M. M., Wu, J., Billups, C. A., Jenkins, J., Santana, V. M., Furman, W. L., & McGregor, L. M. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000148 · Cited by 30
Sholler, G. L. S., Bond, J. P., Bergendahl, G., Dutta, A., Dragon, J. A., Neville, K. A., Ferguson, W. S., Roberts, W. D., Eslin, D. E., Kraveka, J. M., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.436 · Cited by 29
Screening for neuroblastoma: a resurrected idea?
Maris, J. M., & Woods, W. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60500-0 · Cited by 23
Grupp, S. A., Cohn, S. L., Wall, D. A., & Reynolds, C. P. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20769 · Cited by 23
Sholler, G. L. S., Ferguson, W. S., Bergendahl, G., Currier, E. A., Lenox, S. R., Bond, J. P., Slavik, M. A., Roberts, W. D., Mitchell, D. S., Eslin, D. E., et al. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.35077 · Cited by 19
Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
Du, M. Y., Zhang, L., Scorsone, K. A., Woodfield, S. E., & Zage, P. E. (2016) · Scientific Reports · doi:10.1038/srep27458 · Cited by 19
Self-citationFunctional Significance of Aurora Kinase A in Centrosome Amplification and Genomic Instability
Sen, S., Katayama, H. G., & Sasai, K. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_9 · Cited by 18
Schrey, D., Vaidya, S. J., Levine, D., Pearson, A. D. J., & Moreno, L. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000308 · Cited by 18
Soni, S., Pai, V. B., Gross, T. G., & Ranalli, M. A. (2013) · Pediatric Transplantation · doi:10.1111/petr.12202 · Cited by 17
Ipilimumab: First results of a phase I trial in pediatric patients with advanced solid tumors.
Merchant, M. S., Baird, K., Wexler, L. H., Galindo, C. R., & Mackall, C. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.9545 · Cited by 8
Cited by
Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
Johnsen, J. I., Dyberg, C., & Wickström, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00009 · Cited by 277
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Metadata
- Authors
- Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-03-15
- Volume
- 17
- Issue
- 4
- Pages
- 369-386
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2584822160
- Cited by
- 394
- References
- 122
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.